Concluding remarks
MOGAD pathophysiology, disease treatment, and monitoring are currently of high interest in the autoimmune neuroinflammatory diseases research community. So far, most known MRI and OCT characteristics in MOGAD are based on small monocentric studies that yielded some contradicting results, thus multi-centred and prospective studies are necessary to validate findings. Such multi-centred studies are beginning to shed light on this rare disease, such as the Collaborative OCT in NMOSD (CROCTINO) and the PArallel MRI in NMOSD (PAMRINO) studies (133).
In vivo imaging, using MRI and OCT, has given clinicians and researchers insights into the central nervous system affection of this rare disorder at an unprecedented rate. As new technologies and analysis methods continue to be developed, along with the increase in open-sharing and collaborative, prospective studies on the horizon; we believe both MRI and OCT will lead the way towards personalised prognostics and treatment in MOGAD.